Get the Stockscreener App
1.06
1.92%
0.02
Imunon Inc stock is traded at $1.06, with a volume of 39,153.
It is up +1.92% in the last 24 hours and down -24.29% over the past month.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.
See More
Previous Close:
$1.04
Open:
$1.03
24h Volume:
39,153
Relative Volume:
0.44
Market Cap:
$5.95M
Revenue:
$125.00K
Net Income/Loss:
$-14.64M
P/E Ratio:
-0.2051
EPS:
-5.1674
Net Cash Flow:
$-15.06M
1W Performance:
-0.93%
1M Performance:
-24.29%
6M Performance:
-66.35%
1Y Performance:
-77.92%
1-Day Range:
$1.03
$1.07
1-Week Range:
$0.96
$1.12
52-Week Range:
$0.96
$5.29
Imunon Inc Stock (IMNN) Company Profile
Name
Imunon Inc
Sector
Industry
Phone
(609) 896-9100
Address
997 LENOX DRIVE, LAWRENCEVILLE
Compare IMNN vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMNN
Imunon Inc
|
1.06 | 5.95M | 125.00K | -14.64M | -15.06M | -5.1674 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Imunon Inc Stock (IMNN) Latest News
IMUNON Converts $1.2 Million of Debt-to-Equity - GlobeNewswire
A debt swap cuts IMUNON’s outstanding debt by about 43%, with no common shares issued. - Stock Titan
A 7,169-share salary award leaves Imunon (IMNN) chair with 103,921 shares held directly. - Stock Titan
Part of the CEO’s salary came as stock: Imunon (IMNN) granted Stacy Lindborg 6,697 shares. - Stock Titan
At $1.41 a share, Imunon (IMNN) granted its medical chief 4,390 shares in place of part of his cash salary. - Stock Titan
Imunon Inc (NASDAQ: IMNN) Share Price, IMNN Stock News, IMNN Share Price & Updates - kalkine.com.au
Imunon (IMNN) chair takes stock instead of cash pay - Stock Titan
Imunon (IMNN) CEO adds 5,504 shares in stock grant - Stock Titan
Imunon (IMNN) pays its chief medical officer in stock - Stock Titan
IMUNON partners with National Cancer Institute to expand IL-12 DNA plasmid beyond ovarian cancer - AllSci
Imunon (IMNN) Partners with NCI on IMNN-001 Immunotherapy Amid V - GuruFocus
IMUNON Enters CRADA with NCI’s CTEP to Advance IMNN-001 in New Cancer Indications and Combinations - Quiver Quantitative
IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001 - Yahoo Finance
Imunon schedules R&D day for Sept. 23 to discuss IL-12 therapy By Investing.com - Investing.com Australia
Imunon schedules R&D day for Sept. 23 to discuss IL-12 therapy - Investing.com Australia
Imunon schedules R&D day for Sept. 23 to discuss IL-12 therapy - Investing.com Canada
Imunon schedules R&D day for Sept. 23 to discuss IL-12 therapy - Investing.com UK
IMUNON Announces Full Agenda and Speaker Lineup Ahead of - GlobeNewswire
Imunon schedules R&D day for Sept. 23 to discuss IL-12 therapy - Investing.com Nigeria
Imunon (IMNN) Slips 2.5% to $1.54, Approaching Critical Support at $1.46Stock Analysis - siam.in
Imunon (IMNN) Slips 2.5% to $1.56 as Range-Bound Trading Keeps Key Levels in FocusCharm Flow - siam.in
Imunon Inc (IMNN) Insider Sell: General Counsel and Corp Sec Susan Eylward Sells 2,525 Shares - GuruFocus
Insider at Imunon (NASDAQ: IMNN) logs new stock trade - Stock Titan
Imunon (IMNN) insider reports new stock trade - Stock Titan
Imunon (IMNN) counsel takes salary in stock, then sells the same number of shares days later - Stock Titan
Imunon to host R&D day on phase 3 ovarian cancer trial - Investing.com Canada
Imunon to host R&D day on phase 3 ovarian cancer trial - Investing.com India
Imunon to host R&D day on Sept. 23 for ovarian cancer therapy - Investing.com India
Imunon to host R&D day on phase 3 ovarian cancer trial - Investing.com UK
Imunon to host R&D day on Sept. 23 for ovarian cancer therapy - Investing.com UK
Imunon to host R&D day on phase 3 ovarian cancer trial - Investing.com
Imunon (IMNN) Financial Update: EPS Prints Above Forecast on the Day; The Stock Ends Down 3.05% in the Current UpdateGross Profit Margin - dars.gov.et
Imunon (IMNN) Q2 2026 Results: The Available Earnings Metric Delivers a Beat on the Day; After Earnings: The Stock Records a 3.80% Increase in the Current UpdateQuarterly Profit Report - vinanet.vn
Imunon (IMNN) Q2 2026 Results: The Available Earnings Metric Delivers a Beat on the Day; After Earnings: The Stock Records a 3.80% Increase in the Current UpdateGuidance vs Actual - dars.gov.et
Imunon Earnings Call Highlights Survival Gains, Cash Needs - TipRanks
Imunon (IMNN) Q2 2026 Filing Snapshot: The Bottom-Line Figure Outpaces Its Comparison in the Latest Session; Stock Move: Shares Move 1.25% Lower on the DayEarnings Revision Upgrade - vinanet.vn
Imunon (IMNN) General Counsel and Corp Sec Susan Eylward Sells 2,449 Shares - GuruFocus
Imunon (IMNN) CEO takes 6,615 shares instead of cash pay - Stock Titan
Imunon (IMNN) pays CMO with 3,516-share stock grant - Stock Titan
Imunon (IMNN) pays executive chair with 7,147 shares - Stock Titan
Imunon (IMNN) counsel gets stock in lieu of pay, then sells 2,449 shares - Stock Titan
Imunon (IMNN) Q2 2026 Earnings: Narrower-Than-Expected Loss Drives 4.43% BounceProduct Revenue Analysis - vinanet.vn
Imunon Inc. (IMNN) Advances 4.43% as Biotech Stock Tests Key Resistance at $1.73Fair Value Gap - dars.gov.et
Imunon Inc. (IMNN) Advances 4.43% as Biotech Stock Tests Key Resistance at $1.73Gamma Exposure - vinanet.vn
Imunon Inc. (IMNN) Advances 4.43% as Biotech Stock Tests Key Resistance at $1.73Sector Neutral Pair - careplusvn.com
Imunon Inc. (IMNN) Advances 4.43% as Biotech Stock Tests Key Resistance at $1.73Triple MA Cross - dars.gov.et
Armistice Capital (IMNN) discloses 9.99% Imunon stake via Master Fund - Stock Titan
IMUNON to Hold First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 12, 2025 - kalkine.ca
Earnings call transcript: Imunon beats Q2 2026 EPS forecast as shares stay weak - Investing.com UK
Maxim Group Maintains Imunon(IMNN.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Imunon Inc Stock (IMNN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Imunon Inc Stock (IMNN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Eylward Susan | General Counsel and Corp Sec |
Aug 17 '26 |
Sale |
1.63 |
2,449 |
3,993 |
2,896 |
| Eylward Susan | General Counsel and Corp Sec |
Aug 03 '26 |
Sale |
1.57 |
2,541 |
3,977 |
2,896 |
| Eylward Susan | General Counsel and Corp Sec |
Jul 20 '26 |
Sale |
1.78 |
2,150 |
3,830 |
2,896 |
| Eylward Susan | General Counsel and Corp Sec |
Jul 06 '26 |
Sale |
1.88 |
920 |
1,730 |
2,896 |
| Eylward Susan | General Counsel and Corp Sec |
Jun 29 '26 |
Sale |
1.75 |
11,800 |
20,674 |
2,896 |
1.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):